The Pacific Treatment & Research in Psychedelics (TRIP) Program is dedicated to the development of psychedelic-assisted therapies and the scientific exploration of how altered states of consciousness can be harnessed to change behaviour and improve brain health and quality of life.
Pacific Neuroscience Institute
Led by Dr Keith Heinzerling, the TRIP program is exploring the use of psilocybin in the treatment of major depressive disorder and alcohol use disorder in two separate clinical trials. Located in Santa Monica, California, TRIP also offers ketamine-assisted therapy for a range of mental disorders.
Activities
B2C
Research Institute
Clinic
Compounds of Interest
Psilocybin
Explore more company info with a Tree membership
📰 Weekly newsletter about the business of psychedelics
📈 Extended company information (analyst view, fundraising, revenue numbers)
🪄 Priority company page updates